

MEDIA RESOURCES — 2025

Company Profile & Press Kit

A Full-Service Digital Native CRO with Exclusive Proprietary Technology. Built to Run Research Wherever Patients Are.

This press kit is intended for media professionals, journalists, conference organizers, and potential partners seeking background information on Evidilya, its technology platform ECS, and its clinical research capabilities.

Corporate website: www.evidilya.com

Technology platform: www.evidencecapturesystem.com

Press inquiries: press@evidilya.com

01 — COMPANY OVERVIEW

Who We Are

Evidilya is a full-service digital native Contract Research Organization (CRO) founded in 2019. European, independent, and focused on a single mission since day one: generating high-quality clinical and real-world evidence in healthcare — with the precision of science and the agility of technology.

Rooted in one of Europe's most dynamic life sciences ecosystems, our technology and operating model let us work with sponsors and run studies anywhere in the world. Our client base spans EMEAR, the Americas, and Asia-Pacific: pharmaceutical, biotechnology, medtech, food & nutrition, and consumer health care (CHC) companies at every stage of development.

Why Evidilya Exists

Clinical research has a structural problem: it was designed around the convenience of institutions, not the reality of patients. The result is slow enrollment, poor retention, fragmented data, and evidence that does not reflect the populations who will actually use the therapies being developed.

Evidilya was founded to invert this model. Our approach — which we call Life-Integrated Evidence — brings the research to where patients already are: hospitals, community pharmacies, GP offices, and when appropriate, their homes. The operational backbone that makes this possible is ECS, a platform built not to digitize paperwork, but to eliminate it.

We tested this model early in Consumer Health Care — where patients expect zero friction by default, and where study delivery timelines are tighter and less negotiable than anywhere else in clinical research. Sponsors in CHC do not wait. That pressure made us faster, more disciplined, and more accountable. That standard now runs across everything we do.

People and Research First™

People and Research First™ is Evidilya's founding payoff — and its operating principle.

In an industry where technology is often the headline and patients the footnote, Evidilya inverts the hierarchy. Technology is the means. The people it serves — patients who participate in studies, clinicians who run them, researchers who design them — are the only measure of success. Research that does not centre the human experience it is meant to improve is not good science. It is process for its own sake.

This is not a positioning statement. It is the test applied to every product decision, every operational choice, and every new capability we build. Does it make the research better for the people who depend on it? If yes, we build it. If not, we do not.

Momentum, Traction & Speed

Evidilya is in an active phase of growth. New mandate intake in recent months has outpaced the entirety of the prior year — a trajectory reflected in a forward backlog that represents the strongest revenue visibility in the company's history. This growth is driven not by marketing, but by repeat business and word of mouth among sponsors who have experienced our operating model firsthand.

Speed is not a side effect of our model — it is a design principle. ECS eliminates the administrative bottlenecks that slow site activation, patient enrollment, and data delivery. The result is study timelines that are shorter, more predictable, and more consistently met. For sponsors who cannot afford delays, that is not a feature. It is the requirement.



ECS — Evidence Capture System™

ECS is Evidilya's exclusive proprietary clinical research platform — a complete virtual ecosystem designed to run hybrid and fully decentralized clinical trials at global scale. It is not a third-party EDC with a custom interface. Every component is built and owned by Evidilya, designed to operate as an integrated whole rather than a stack of connected tools.

The platform is accessible at → www.evidencecapturesystem.com

ViSA Virtual Intelligent Study Assistant	The coordination layer at the heart of ECS New Release (January 2026). ViSA unifies all study stakeholders — sponsors, investigators, coordinators and patients — in a single virtual environment. It automates communication flows, clinical alerts, participant journey monitoring and real-time sync across all modules. One dashboard. Every site. Any geography. Real time.
Lucah™ Patient Engagement App	Study-specific mobile application for direct participant engagement. Covers ePRO, eDiary, eCOA, adherence tracking and direct communication with the study team. Natively integrated with ViSA for seamless real-time coordination.
DCM Data Capture Module	Advanced clinical data capture with GCP/GXP-compliant workflows, real-time validation and cross-site consistency checks. Designed for hybrid and fully decentralized trial architectures.
Datacare™ Data Governance & Security	Data governance infrastructure with biometric server architecture, daily backup and disaster recovery. Full compliance with GCP, GDPR and international data integrity standards. ECS has been independently qualified.
DDT Deep Dialogue Technology	Proprietary qualitative analytics engine that transforms patient-reported natural language into structured scientific evidence — enabling RWE generation from sources beyond traditional clinical instruments.

End-to-End Study Management

Evidilya manages the complete lifecycle of a clinical study. This means a single accountable partner from the first protocol discussion to the final regulatory submission — with the same proprietary platform running every phase.

The integrated architecture of ECS translates directly into operational performance: faster site activation, accelerated patient enrollment through the PHYGITAL-CROWD model, and real-time data flow that eliminates the lag between clinical events and database lock. Studies run on ECS are designed to close faster, with fewer deviations and stronger data integrity from first patient in to last patient out.

Protocol Design & Regulatory Strategy — Protocol writing, ethics committee and regulatory submissions (EMA, FDA, local authorities), multi-jurisdiction amendment management.

Site Selection & Activation — Site identification, feasibility assessment, contracting, investigator training and GCP certification.

Clinical Operations & Monitoring — On-site and remote CRA monitoring, deviation management, risk-based monitoring frameworks, source data verification.

Patient Recruitment — PHYGITAL-CROWD proprietary enrollment strategy combining physical touchpoints (hospitals, pharmacies, GPs) with targeted digital outreach for diverse, representative patient populations.

Direct-to-Participant (D-T-P) — Home delivery of investigational product, remote sample collection, home nursing support — eliminating geographic barriers to trial participation.

Data Management & Biostatistics — Database design, data cleaning, statistical analysis and reporting per ICH/EMA standards.

Medical Writing & Publication — CSR drafting, abstract and manuscript preparation, regulatory dossiers, scientific publications.

13 Therapeutic Areas. Dedicated Teams. Specialized Networks.

Each therapeutic area at Evidilya is supported by a dedicated clinical team and a network of pre-qualified sites with specific expertise.

Oncology

Cardiovascular

Metabolic & Endocrine

Central Nervous System

Respiratory & Immunology

Rare & Orphan Diseases

Infectious Diseases

Gastroenterology & Hepatology

Dermatology

Nutrition & Food Science

Aesthetic Medicine

Gynecology & Women's Health

Pediatrics

European. Independent. Global.

Headquarters: Milan, Italy

Structure: Fully independent

Active reach: EMEAR — Asia-Pacific — Latin America — North America

International sponsors: >55% of Evidilya's client base is headquartered outside Italy — pharma, biotech, CHC and medtech companies from EMEAR, Americas and Asia-Pacific

Regulatory frameworks: ICH E6(R3) — EMA — EU Clinical Trials Regulation — FDA — GCP/GXP

Certification: GCP-Iso27000 compliant.

Available Media Resources

The following assets are available on request via press@evidilya.com or through the press section at www.evidilya.com

Press releases — Full-text press releases in English and Italian, available in .docx and .pdf format.

Company logos — Evidilya logo and ECS / Evidence Capture System™ logo in vector (SVG, EPS) and raster (PNG) formats, light and dark versions.

Executive portraits — High-resolution photography of Leadership team available on request.

Platform screenshots — ECS interface visuals, ViSA coordination layer, Lucah™ App screens — available under media license for editorial use.

B-roll / video — Available on request for broadcast and digital media.

Key Websites

Corporate: www.evidilya.com

Technology platform: www.evidencecapturesystem.com

Vision & Mission

Our vision and mission are detailed at www.evidilya.com

Press Contact

Press office: SPRIM — PR & Healthcare Communications

Press office email: ufficiostampa@sprim.it

Company email: press@evidilya.com

Response time: All media enquiries are responded to within 24 hours on working days.

ABOUT EVIDILYA

Evidilya is a fully independent, full-service digital native CRO founded in 2019 and headquartered in Milan, Italy. European by identity, global by reach. The company designs and executes clinical studies and real-world evidence programs for pharmaceutical, biotechnology, medtech and food & nutrition sponsors worldwide, operating exclusively on its proprietary ECS (Evidence Capture System) platform. People and Research First™.

www.evidilya.com | www.evidencecapturesystem.com | press@evidilya.com

The Evidence Standard

Evidilya's Value Charter — For partners, sponsors and media

The Evidence Standard is Evidilya's operational manifesto. It is not a mission statement — it is the code that governs every study, every data point, every interaction with patients, investigators, and sponsors.

01

Clinical Rigor, Human Interface

An easy-to-use system is methodologically superior. Our technology reduces human error because it adapts to people's lives, not the other way around. The simplicity of the interface is the result of scientific rigor, not its negation.

02

Frictionless Science

Research must not be a burden for the physician. We automate the digital translation of clinical data to give time back to care. Every hour saved on administration is an extra hour devoted to the patient.

03

Life-Integrated Evidence

We bring the trial to where life happens. From community pharmacies to territorial medicine, every touchpoint is an opportunity to generate high-quality Real-World Evidence. The laboratory of the future is the real world.

04

Artificial Integrity

AI in ECS is not an abstraction — it is a guarantor. It monitors, validates, and protects clinical data in real time, accelerating patient access to new therapies. Artificial intelligence in service of scientific integrity.

05

People and Research First™

Our tagline is our practice. Technology is the means; patient wellbeing and research integrity are the only ends. Every product decision, every operational choice, starts from one question: what is best for the patient and for the quality of the evidence?

Technical reference for science and business journalists

CRO (Contract Research Organization) — An organization managing the full or partial execution of clinical studies on behalf of pharmaceutical, biotech, or medtech sponsors. Evidilya operates as a full-service CRO: managing the entire study lifecycle.

DCT (Decentralized Clinical Trial) — A trial in which some or all activities occur outside traditional clinical sites using digital technologies and direct-to-participant services. Formally endorsed by ICH E6(R3) and EMA guidelines.

RWE (Real-World Evidence) — Clinical evidence generated from data collected in routine medical practice. Increasingly required by regulators and payers for post-approval decisions and label extensions.

CHC (Consumer Health Care) — The segment of healthcare products available without prescription — OTC medicines, supplements, medical devices for self-care. In clinical research, CHC studies demand the highest standards of patient-centricity and delivery speed.

PHYGITAL-CROWD — Evidilya's proprietary enrollment strategy combining physical touchpoints (clinical sites, pharmacies, GPs) and digital outreach to reach diverse, representative patient populations at scale.

D-T-P (Direct-to-Participant) — Operational model enabling investigational product delivery, sample collection, and clinical support directly at the participant's home, eliminating geographic barriers to trial participation.

ICH E6(R3) — The updated international Good Clinical Practice guideline formally endorsing risk-based, technology-driven trial conduct including decentralized methodologies.

ViSA (Virtual Intelligent Study Assistant) — Evidilya's proprietary coordination layer within ECS New Release. Connects all study stakeholders in one virtual environment with automated communication, clinical alerts, and real-time participant journey monitoring.

Life-Integrated Evidence — Evidilya's operating model for evidence generation: bringing research to where patients live, rather than requiring patients to come to research.

Artificial Integrity — Evidilya's definition of AI's role in clinical research: not a decision-maker, but a guarantor of data quality, consistency, and scientific integrity in real time.